

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RNA sequencing and CHIP sequencing data described in this manuscript are deposited in the NCBI Gene Expression Omnibus (GSE160684 for RNA seq and GSE160597 for CHIP seq). Accession Token codes for reviewer are ulixqyuszrwjvap (RNA seq) and oxmpkqkotfdbuz (CHIP seq).

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Most experiments are done in triplicates except for animal studies, which involved at least 5 mice per experimental group (age and sex matched).
Data exclusions	No data were excluded.
Replication	All attempts at replication reliably supported conclusions described in the manuscript.
Randomization	Samples or animal were randomly allocated to each group without bias.
Blinding	This is not relevant to this study, since no subjective rating of data was involved.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	Antisera are described in the manuscript. We used all commercial antibodies as a 1:1000 dilution, except alpha-tubuline and HSP90 (1:3000). We used all home made antibodies as a 1:3000 dilution. Cell Signaling Technologies (CRTC3; #2720, pPKA substrate; #9624, c/EBPa; #8178, SIK2; #6919, HDAC4; #5392, Glut4; #2213, p-HSL S563; #4139, p-Akt S473; #4060, p-p38 T180/Y182; #4511, p-p65 S536; #3033, Ac-p65 K310; #12629, p-JNK T183/Y185; #4668, p-AMPK T172; #2535), Santa Cruz Biotechnology (c/EBPa; sc-61, ATF3; sc-518032, JunB; sc-8051, HSP90; sc-7947), Millipore (SIK2; 07-1378, a-tubulin; 05-829), LS Bio (ADRB3; LS-C120555), Boster Bio (CD11b; PB9140), Invitrogen (p-IRS1 S307; PA1-1054, p-SIK2 Thr175; PA5-64607), ABclonal (PTGER3; A4057) and homemade (CRTC2, p-CRTC2 S171, p-CRTC2/3 S275/273).
Validation	All commercial antibodies validated by manufacturer using relevant stress/stimulus and cited in more than 3 publications. Home-made phospho-specific antibodies validated with stimulus. Knockout tissue and cell line samples also used to validate in house antisera.

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	All cell lines (293T, 3T3L1, HIB1b, Raw264.7) used in this study are from ATCC.
Authentication	We did not authenticate the 293T cells. We authenticated 3T3L1 and HIB1b cells by checking for induction of adipogenic factors after adipocyte differentiation in vitro.
Mycoplasma contamination	Cell lines used in this study were not contaminated with mycoplasma (Lonza; LT07-118).

Commonly misidentified lines  
(See [ICLAC](#) register)

None of the cell lines we used is listed in ICLAC database.

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

Laboratory animals

We used C57BL/6 strain of mice. We used male CRT2/3 double floxed mice with or without adiponectin-Cre recombinase. Age range is 11-18 weeks.

Wild animals

No wild animals are used in our study.

Field-collected samples

No field-collected samples were involved in our study.

Ethics oversight

All procedures involving the use of animals were performed in accordance with the guidelines presented by Salk Institute's Animal Care and Use Committee.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## ChIP-seq

### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

*May remain private before publication.*

<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160597>

Secure token

oxmpkqkotfidbuz

Files in database submission

GSM4875778  
3T3L1-CRTC2-control  
GSM4875779  
3T3L1-CRTC2-FSK  
GSM4875780  
3T3L1-CRTC2-TNFa  
GSM4875781  
3T3L1-CRTC2-FSKTNFa  
GSM4875782  
3T3L1-p65-control  
GSM4875783  
3T3L1-p65-FSK  
GSM4875784  
3T3L1-p65-TNFa  
GSM4875785  
3T3L1-p65-FSKTNFa  
GSM4875786  
3T3L1-H3AcK27-control  
GSM4875787  
3T3L1-H3AcK27-FSK  
GSM4875788  
3T3L1-H3AcK27-TNFa  
GSM4875789  
3T3L1-H3AcK27-FSKTNFa  
GSM4875790  
input-control  
GSM4875791  
input-FSK

Genome browser session  
(e.g. [UCSC](#))

None

### Methodology

Replicates

None

Sequencing depth

Sample Read number Uniquely mapped reads Average read length (nt) Single/double end  
CRTC2-control 18885214 7811598 50.764 single  
CRTC2-FSK 16438040 9303759 50.760 single

	<p>CRTC2-TNFa 26472345 9414862 50.784 single  CRTC2-FSKTNFa 31807394 13026109 50.782 single  p65-control 26505421 18504780 50.777 single  p65-FSK 24941629 4559667 50.769 single  p65-TNFa 26904732 6106981 50.772 single  p65-FSKTNFa 20490261 4891561 50.765 single  H3AcK27-control 27601287 20524212 50.798 single  H3AcK27-FSK 9832884 8044186 50.730 single  H3AcK27-TNFa 26904732 6106981 50.772 single  H3AcK27-FSKTNFa 25729060 18273689 50.786 single  input-control 25700078 19561531 50.768 single  input-FSK 27193734 17643239 50.768 single</p>
Antibodies	<p>CRTC2 in house serum #6865</p> <p>p65 Cell Signaling #8242</p> <p>H3AcK27 AbCam Ab4729</p>
Peak calling parameters	<p>Reads were aligned to the mm10 genome build using STAR.</p> <p>Peaks were called with Homer using the findPeaks program against input (no IP) DNA files. For CRTC2 and p65, the "factor" mode was used e.g.:</p> <pre>findPeaks CRTC23T3FSK_tagdir/ -style factor -o CRTC2FSKpeaks -i input3T3FSK_tagdir/</pre> <p>For H3AcK27, the "histone" mode was used e.g.:</p> <pre>findPeaks HAcK3T3FSK_tagdir/ -style histone -o HAcKFSKpeaks -i input3T3FSK_tagdir</pre>
Data quality	<p>Peak quality was calculated using Homer (findPeaks) with default parameters: FDR = 0.001, tag density in peaks requires four fold greater than in the surrounding 10kb region and four fold greater than input.</p> <p>p65 immunoprecipitation was not efficient (0.63% based on tags found in peaks versus background for FSK+TNFa treatment), but NFkB binding motif was clearly enriched under p65 peaks.</p> <p>Number of peaks that passed thresholds:</p> <p>Sample Peak number  CRTC2-control 5188  CRTC2-FSK 11749  CRTC2-TNFa 19527  CRTC2-FSKTNFa 14171  p65-control 214  p65-FSK 2969  p65-TNFa 2404  p65-FSKTNFa 4221  H3AcK27-control 52321  H3AcK27-FSK 38684  H3AcK27-TNFa 49754  H3AcK27-FSKTNFa 42227</p>
Software	<p>STAR for alignment of reads to the mm10 mouse genome build.</p> <p>HOMER for peak calling, quantification, annotation and visualization on the UCSC genome browser.</p>

## Flow Cytometry

### Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

## Methodology

Sample preparation

primary stromal vascular fraction (SVF) cells were isolated from mouse epididymal adipose tissue. Following isolation, SVF cells were labeled with fluorochrome tagged markers and then washed (HBSS +2% FBS) and analyzed.

Instrument

BD FACS LSRII(BD Biosciences)

Software

The cytometer ran BD FACSDiva acquisition software and FlowJo v9.7.5.

Cell population abundance

Cell sorting was not employed

Gating strategy

Using the Initial FSC-A/SSC-A gating, cell debris was excluded by gating on the main cell population. Then cells were gated in FSC-W/FSC-A to discriminate single cells; then cells were gated in SSC-W/SSC-A to discriminate live cells. Positive threshold for each marker was defined on WT cells in control group and then identical positive threshold was applied to other cells in test group. Un-labelled cells were used for selecting negative population.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.